Fig. 1: Schematic workflow and clinical features of study patients and prospective sequencing samples in the FUSCC-BC cohort. | Cell Discovery

Fig. 1: Schematic workflow and clinical features of study patients and prospective sequencing samples in the FUSCC-BC cohort.

From: Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities

Fig. 1: Schematic workflow and clinical features of study patients and prospective sequencing samples in the FUSCC-BC cohort.The alternative text for this image may have been generated using AI.

a Schematic representation of workflow for the targeted sequencing analyses in our study, including cohort establishment, sample preparation, panel sequencing, and optimization of genomics-guided treatment. b Treatment information for each molecular subtype in the surgery cohort, neoadjuvant cohort, and advanced cohort. The size of the circles represents the number of patients with the corresponding drugs. NAT, neoadjuvant therapy. c The clinical characteristics of our cohort compared with those reported in prior breast cancer sequencing studies (MSKCC and TCGA). See also Supplementary Table S2. d The distribution of biopsied metastatic sites grouped by molecular subtype. The width of connecting lines is proportional to the number of patients with the respective molecular subtype and biopsy site. A portion of a was created with BioRender.com.

Back to article page